Chemotherapy Induced Anemia Clinical Trial
Official title:
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept treatment of chemotherapy-induced anemia (CIA) in participants with metastatic breast cancer. Hematopoietic response was defined as an increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of sotatercept in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05301517 -
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
|
Phase 3 | |
| Completed |
NCT00272662 -
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
|
Phase 2 | |
| Completed |
NCT00144495 -
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
|
Phase 3 | |
| Not yet recruiting |
NCT06075030 -
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
|
Phase 2 | |
| Completed |
NCT00144482 -
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
|
Phase 3 | |
| Completed |
NCT04076943 -
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
|
Phase 2 |